LUNG CANCER

Register Now

Specimen Handling & Ancillary Testing

General Handling Considerations

+Pathologists' Staging of Multiple Foci of Lung Cancer

Pathologists' Staging of Multiple Foci of Lung Cancer

Robert J. Homer, MD, PhD

The article highlights the difficulties with staging multiple synchronus lung tumors. This paper should be added also: Frank Schneider, Veronica Derrick, Jon M Davison, Diane Strollo, Pimpin Incharoen and Sanja Dacic. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. Modern Pathology (2016) 29, 735–742; doi:10.1038.
Register now to review full resource. Or, if you have registered, login now.

+Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing

Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing

Aisner DL, Rumery MD, Merrick DT, et al.

The authors describe their techniques and experience in handling small biopsy specimens to increase yields for ancillary testing. This is a very helpful refernece for laboratories looking to decerase QNS rates.
Register now to review full resource. Or, if you have registered, login now.

Immunohistochemistry (IHC) and special stains

+Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma

Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma

Kushitani K, et al.

A study evaluating the best panel of IHC markers for distinguishing solid adenocarcinoma from solid epithelioid mesothelioma
Register now to review full resource. Or, if you have registered, login now.

+The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases

Thunnissen E, et al.

A study of diagnostic reproducibility of small cell carcinoma, evaluting the use of IHC to more accurately diagnose small cell carcinoma.
Register now to review full resource. Or, if you have registered, login now.

+Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society

Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society

Sholl LM, et al.

A nice review of the current state of PD-L1 testing and challenges associated with implementation of this testing in laboratories
Register now to review full resource. Or, if you have registered, login now.

+Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society

Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society

Erik Thunnissen, Timothy Craig Allen, Julien Adam, et al.

This article discusses the application and utility of immunohistochmestry stains including predictive biomarkers in non-small cell lung cancer
Register now to review full resource. Or, if you have registered, login now.

+Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society

Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society

Roy-Chowdhuri S, Aisner DL, Allen TC, Beasley MB, et al.

This article focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era.
Register now to review full resource. Or, if you have registered, login now.

+Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis

Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis

Kadota, Kyuichi MD, PhD*,†,‡; Nitadori, Jun-ichi MD, PhD*,§; Rekhtman, Natasha MD, et al.

This article discusses the importance of using immunohistochemistry in accurate classification of lung carcinomas, even on resection specimens.
Register now to review full resource. Or, if you have registered, login now.

+MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma

MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma

Amatya VJ, et al.

A study evaluating the utility of MUC4 as an IHC marker of mesothelial differentiation for evaluation of malignant sarcomatoid pleural proliferations
Register now to review full resource. Or, if you have registered, login now.

FISH and molecular testing

+Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors

Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors

Rashmi S. Goswami, MD, PhD, Rajyalakshmi Luthra, PhD, Rajesh R. Singh, PhD, et al.

In this study they identified the most common factors that affect NGS efficacy.
Register now to review full resource. Or, if you have registered, login now.

+BRAF Alternations as Therapeutic Targets in Non-Small-Cell Lung Cancer

BRAF Alternations as Therapeutic Targets in Non-Small-Cell Lung Cancer

Tu Nguyen-Ngoc, MD, PhD; Hasna Bouchaab, MD; Alex A Adjei, MD, PhD, et al.

BRAF mutation as a targetable driver mutation is disucssed in this article.
Register now to review full resource. Or, if you have registered, login now.

+Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris, MD; Bruce E. Johnson, MD; Lynne D. Berry, PhD, et al.

Actionable drivers were studied in a large cohort of over 1000 patients. Actionable mutations were detected in 64% of lung adenocarcinomas.
Register now to review full resource. Or, if you have registered, login now.

+Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer

Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer

Chiara Casadio, MD; Juliana Guarize, MD; Stefano Donghi, MD, et al.

The utility of EGFR/KRAS/ALK testing was studied in EBUS samples and showed that EBUS can be effectively used not just for diagnosis but also for complete mutational testing
Register now to review full resource. Or, if you have registered, login now.

+Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool

Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool

Jamal Carter, MD; Li-Hui Tseng, MD, PhD, Gang Zheng, MD, PhD, et al.

The authos showed that there are different variants of BRAF mutations in various tumors, including lung adenoarcinomas. lung adenocarcinomas also showed more unique BRAF mutations and a higher prevalence of exon 11 mutations and non–codon 600.
Register now to review full resource. Or, if you have registered, login now.

+Comparison of Next-Generation Sequencing and Mutation-Specific Platforms in Clinical Practice

Comparison of Next-Generation Sequencing and Mutation-Specific Platforms in Clinical Practice

John W. J. Hinrichs, PhD; W.T. Marja van Blokland; Michiel J. Moons, et al.

Single gene assay is compared to next generation sequencing for EGFR and KRAS, and authors found comparable results for these two genes.
Register now to review full resource. Or, if you have registered, login now.

+Testing for ROS1 in non-small cell lung cancer: a review with recommendations

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

Bubendorf L, et al.

A nice review of ROS1 testing methods and handling issues.
Register now to review full resource. Or, if you have registered, login now.

+Biomarkers in Lung Adenocarcinoma: A Decade of Progress

Biomarkers in Lung Adenocarcinoma: A Decade of Progress

Lynette M. Sholl, MD

This is an overview of the molecular biomarkers that are used prognostically and therapeutically in advanced lung adeocarcioma
Register now to review full resource. Or, if you have registered, login now.

+KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma

KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma

Kadota, Kyuichi MD, PhD; Sima, Camelia S. MD, MS; Arcila, Maria E. MD, et al.

The prognostic significance of KRAS and EGFR driver mutations is investigated in a large cohort of early-stage lung adenocarcinomas.
Register now to review full resource. Or, if you have registered, login now.

+Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation

Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation

Kadota, Kyuichi MD, PhD*,†,‡; Yeh, Yi-Chen MD*; D’Angelo, Sandra P. MD, et al.

This study investigates the association between mucinous histologic features of lung adenocarcinoma and driver mutations. They find mucinous lung adenocarcinomas are associated with KRAS mutation.
Register now to review full resource. Or, if you have registered, login now.

+Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

Kris MG, Johnson BE, Berry LD, et al.

This article reviews the findings from the Lung Cancer Mutation Consortium project. The project looked at frequency of 10 driver mutations in tumors from 1007 patients.
Register now to review full resource. Or, if you have registered, login now.

+Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Lindeman NI, Cagle PT, Beasley MB, et al.

Reviews guidleines for testing EGFR and ALK alterations.
Register now to review full resource. Or, if you have registered, login now.

+UMolecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis

Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis

DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA.

Study analyzes one center's TAT for molecular testing, finding an average of 9 working days from the time the material is received in the laboratory.
Register now to review full resource. Or, if you have registered, login now.

+Improving Selection Criteria for ALK Inhibitor Therapy in Non–Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry

Improving Selection Criteria for ALK Inhibitor Therapy in Non–Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry

Jiang, Long MD, PhD; Yang, Haihong MD, PhD; He, Ping MD, PhD, et al.

This study evaluates the diagnostic role of ALK immunohistochemistry (IHC) in identification of ALK rearrangement compared to FISH. Authors conclude that IHC scores of 0 and 3+ were nearly 100% concordant with FISH-negative and FISH-positive status, respectively. However, IHC scores 1+ and 2+ might require further confirmatory testing by FISH assay. IHC assay using D5F3 and 5A4 antibodies reliably detected NSCLC with ALK rearrangement and may be useful as a screening method to identify these tumors.
Register now to review full resource. Or, if you have registered, login now.

This website is sponsored by:

 Founding Sponsor

Copyright © 2017. The American Society for Clinical Pathology. All rights reserved.